KKR agreed to acquire Integer Holdings Corporation for $5.7 billion in cash, removing the Plano, Texas-based medical device contract manufacturer from public markets. The transaction values Integer at $127 per share, a 28% premium to the 30-day volume-weighted average price through January 10. Integer shareholders vote in Q2 2025, with close expected by mid-year pending HSR and foreign investment clearances.
Integer manufactures components and finished devices for cardiology, neuromodulation, and portable medical markets. The company reported $1.54 billion in trailing twelve-month revenue as of September 2024, with 18.2% EBITDA margins. KKR's thesis centers on margin improvement through operational leverage and strategic repositioning away from lower-margin legacy battery contracts. Integer's customer base includes every major cardiac rhythm management OEM and three of the four leading neuromodulation platforms. The company holds 47% share in rechargeable battery systems for implantable neurostimulators, a segment growing at 12-15% annually as spinal cord stimulation and deep brain devices proliferate.
This marks KKR's return to large-scale healthcare manufacturing after the $13 billion Envision Healthcare take-private in 2018 and the $2.1 billion PRA Health Sciences acquisition in 2021. The Integer deal enters a contract manufacturing segment where consolidation has accelerated. Carlyle acquired Paragon Medical for $1.1 billion in August 2023. Clayton Dubilier & Rice closed on Aesculap Implant Systems for $1.4 billion in October 2024. KKR's edge lies in Integer's installed base within high-barrier neuromodulation accounts, where switching costs run 18-24 months due to regulatory validation cycles. The firm will likely pursue bolt-on acquisitions in adjacent catheter and lead manufacturing, targeting 200-300 basis points of margin expansion over a four-year hold.
Allocators should monitor Integer's Q1 2025 earnings in late April for any pre-close customer concentration shifts, particularly in the top three accounts that represent 41% of revenue. Watch for KKR credit fund participation in the financing package, which typically signals internal conviction on cash flow stability. The neurostimulator battery segment faces potential disruption from solid-state battery entrants expected to file FDA submissions in late 2025 or early 2026, compressing replacement cycle economics. Any material design-win announcements from competitors between now and close would alter the margin expansion timeline.
Integer's public float was $4.2 billion before announcement. KKR is using $3.8 billion in debt financing arranged by Goldman Sachs and JPMorgan, implying 6.2x leverage on forward EBITDA. The remaining $1.9 billion comes from KKR's Americas XII and Next Generation Technology Growth Fund II vehicles.